Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00010663/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective of this study is to assess the reduction in insulin dose from baseline at Week 24 while keeping the blood glucose levels controlled (maintaining HbA1c values) when ipragliflozin is administered once daily for 24 weeks in patients with type 2 diabetes mellitus receiving insulin therapy.
提供机构：
Vivli
创建时间：
2024-10-10
